← Back to Search

NMDA Receptor Antagonist

Memantine for Healthy Subjects

Phase 4
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 and 14 days post baseline
Awards & highlights

Study Summary

This study is evaluating whether a drug may help improve auditory processing for individuals with schizophrenia.

Eligible Conditions
  • Healthy Subjects
  • Schizophrenia
  • Schizoaffective Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 and 14 days post baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 and 14 days post baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gamma Auditory Steady-state Response (ASSR). The Primary Unit of Measure of Auditory Steady State Response (ASSR) is Gamma Evoked Power (γEP), Expressed as "Microvolts-squared".
Mismatch Negativity (MMN); Unit of Measure of MMN is Microvolts.
Prepulse Inhibition (PPI)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: MemantineActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,121 Previous Clinical Trials
1,520,882 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025